Affected person-reported outcomes had been comparable for Fotivda with or with out Opdivo in superior clear cell RCC: © inventory.adobe.com
Including Fotivda (tivozanib) to Opdivo (nivolumab) was proven to have comparable patient-reported outcomes (PROs) versus Fotivda monotherapy for the remedy of domestically superior or metastatic clear cell renal cell carcinoma (RCC) whose illness progressed on one or two systemic therapies and no less than one immune checkpoint inhibitor (ICI), in response to outcomes from the part 3 TiNivo-2 research.
Glossary:
Affected person-reported outcomes: stories on a affected person’s well being situation that come instantly from the affected person themselves
Practical Evaluation of Most cancers Remedy Kidney Most cancers Symptom Index-Illness-Associated Signs (FKSI-DRS): a instrument used to measure the severity of signs particularly associated to kidney most cancers in sufferers
European Group for Analysis and Remedy of Most cancers (EORTC) QLQ-C30 questionnaires: an evaluation that measures high quality of life in sufferers with most cancers
Intent-to-treat inhabitants: all sufferers who had been initially randomly assigned to completely different remedy teams, no matter whether or not they truly acquired the assigned remedy or accomplished the research
ECOG efficiency standing of 0 or 1: a scoring system on a affected person’s means to finish actions of every day residing. A rating of 0 or 1 signifies a affected person who’s totally energetic or somebody who’s restricted in bodily strenuous exercise however ambulatory and capable of perform mild work, respectively
Development-free survival: the time throughout and after remedy when a affected person with most cancers lives with out their illness worsening
General survival: the size of time from prognosis or remedy initiation when a affected person with most cancers continues to be alive
Goal response fee: the proportion of sufferers whose most cancers shrinks or disappears after remedy
Proteinuria: the next than regular stage of protein in urine, which can be an indicator of kidney injury
Information on PROs, which had been introduced on the 2025 Genitourinary Cancers Symposium, demonstrated that Fotivda maintained the imply scores for the Practical Evaluation of Most cancers Remedy Kidney Most cancers Symptom Index-Illness-Associated Signs (FKSI-DRS) and European Group for Analysis and Remedy of Most cancers (EORTC) QLQ-C30 questionnaires.
Within the intent-to-treat (ITT) populations from the Fotivda/Opdivo versus Fotivda monotherapy arms, respectively, the imply FKSI-DRS scores at baseline had been 28.8 versus 29.3; at week 24, these scores had been 29.9 versus 29.4. The imply EORTC QLQ-C30 scores at baseline had been 63.4 versus 66.2 within the mixture versus monotherapy arms, respectively; at week 24, these imply scores had been 68.7 versus 64.8. Sufferers handled with the mixture versus monotherapy within the second line had imply FKSI-DRS scores at baseline of 29.5 versus 29.1; at week 24, these imply scores had been 30.1 versus 29.3. Imply EORTC QLQ-C30 scores at baseline within the mixture versus monotherapy arms within the second line had been 65 versus 67.1; these imply scores at week 24 had been 68.7 versus 64.6. Within the third-line setting, imply FKSI-DRS scores at baseline had been 27.6 versus 29.5; these imply scores at week 24 had been 29.5 versus 29.6. Imply EORTC QLQ-C30 scores at baseline within the mixture versus monotherapy arms within the third had been 60.5 versus 64.9, with imply scores at week 24 of 68.6 versus 65.1.
“Within the [Fotivda monotherapy] arm, enchancment in FKSI-DRS and EORTC QLQ-C30 scores had been numerically better in sufferers receiving second-line remedy than third-line remedy, whereas … fewer sufferers reported deterioration within the second line than within the third line,” lead research writer Dr. Kathryn Beckermann and coauthors wrote in a poster introduced on the assembly.
Beckermann is an assistant professor within the Division of Medication, Division of Hematology and Oncology at Vanderbilt Faculty of Medication in Nashville, Tennessee.
Fotivda Background and TiNivo-2 Design
The TiNivo-2 research in contrast Fotivda/Opdivo with Fotivda monotherapy in sufferers with domestically superior or metastatic clear cell RCC following development on one or two systemic therapies and no less than one ICI. The trial enrolled sufferers who had radiographic development throughout or after no less than six weeks of remedy with an ICI within the first or second line; recovered from unintended effects of earlier therapies to grade 1 or baseline; had confirmed clear cell RCC; measurable illness; and an ECOG efficiency standing of 0 or 1.
Eligible sufferers had been randomly assigned to obtain Fotivda/Opdivo (171 sufferers) or Fotivda monotherapy (172 sufferers). Cycles had been 28 days, and remedy was continued till development or unacceptable toxicity. All sufferers discontinued Opdivo after two years of remedy.
Researchers has a number of outcomes of curiosity together with progression-free survival (PFS), general survival goal response fee and period of response. An exploratory space of curiosity was high quality of life (QOL).
Extra PROs and Efficacy Information
The FKSI-DRS and EORTC QLQ-C30 abstract scores confirmed that there was not a major change in symptom scores over time within the mixture and monotherapy arms. Particularly within the second and third line, sufferers from each arms additionally demonstrated an analogous pattern in FKSI-DRS and EORTC QLQ-C30 abstract scores, with maintained symptom scores over time.
Concerning QOL scores, FKSI-DRS and EORTC QLQ-C30 questionnaires reported constant traits and proportions of sufferers with improved (will increase in scores of no less than 3 factors at any level in the course of the research), secure (a change in rating of three or fewer factors confirmed on the subsequent consecutive go to), or deteriorated signs (lower in rating of no less than 3 factors at any level in the course of the research). Primarily based on the FKSI-DRS questionnaire, sufferers from the mixture versus monotherapy arms, respectively, had improved (28.2% versus 22.9%), secure (47.2% versus 53.5%), and deteriorated signs (24.6% versus 23.6%). The EORTC QLQ-C30 questionnaire amongst sufferers within the mixture versus monotherapy arms, respectively, revealed improved (27.7% versus 21.3%), secure (48.9% versus 53.7%), and deteriorated signs (23.4% versus 25%).
“Roughly 75% of all sufferers reported improved or secure kidney most cancers and cancer-treatment associated signs in each remedy arms,” the research authors wrote within the poster.
In sufferers handled with the mixture versus monotherapy within the second line, respectively, FKSI-DRS mirrored improved (28% versus 27.5%), secure (52.7% versus 53.8%), and deteriorated (19.4% versus 18.7%) health-related QOL (HRQOL) scores. Within the third line, sufferers within the mixture versus monotherapy arms, respectively, had improved (28.6% versus 15.1%), secure (36.7% versus 52.8%), and deteriorated (34.7% versus 32.1%) HRQOL scores. Primarily based on EORTC QLQ-C30, sufferers from the mixture versus monotherapy arms, respectively, handled within the second line had improved (27.8% versus 23%), secure (52.2% versus 56.3%), and deteriorated (20% versus 20.7%) HRQOL scores. Sufferers handled with the mixture versus monotherapy within the third line, respectively, confirmed improved (27.7% versus 18.4%), secure (42.6% versus 49%) and deteriorated (29.8% versus 32.7%) HRQOL scores.
The speed of PFS occasions that occurred in sufferers handled within the mixture (111 sufferers) versus monotherapy (105 sufferers) arms, respectively, within the second line, was 64% versus 61%; median PFS was 7.3 months versus 9.2 months. Amongst sufferers handled with the mixture (60 sufferers) versus monotherapy (67 sufferers) within the third line, PFS occasions occurred in 78% versus 72%, respectively; median PFS was 4.8 months versus 5.5 months.
Security Information
The kind and frequency of security occasions within the Fotivda monotherapy arm had been in keeping with the identified security profile of Fotivda, confirming its tolerability.
Remedy-emergent unintended effects that occurred in 15% or extra of sufferers within the mixture versus monotherapy arms, respectively, included hypertension (37% versus 40%), fatigue (29% versus 40%), diarrhea (30% versus 36%), nausea (16% versus 28%), decreased urge for food (22% versus 27%), vomiting (12% versus 21%), weak point (23% versus 21%), proteinuria (10% versus 18%), constipation (10% versus 17%), joint ache (16% versus 16%), cough (16% versus 15%), hypothyroidism (9% versus 15%), anemia (17% versus 9%) and itching (16% versus 6%).
“For sure [treatment-emergent side effects], comparable to fatigue, nausea, vomiting, proteinuria, and hypothyroidism, the mixture group confirmed decrease numerical charges,” the research authors wrote. “Nevertheless, this was not the case for anemia [or] pruritus, which confirmed the reverse. The decrease dose within the mixture [group] probably explains the decrease fee of [treatment-emergent side effects] related to VEGF [tyrosine kinase inhibitors].”
Reference
“Affected person-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in sufferers with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): outcomes of the part 3 TiNivo-2 research” by Dr. Kathryn Beckermann, et al., Journal of Medical Oncology.
For extra information on most cancers updates, analysis and schooling, don’t neglect to subscribe to CURE®’s newsletters right here.
